Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Decrease in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 15,700 shares, a drop of 74.1% from the February 29th total of 60,600 shares. Based on an average daily volume of 136,600 shares, the short-interest ratio is presently 0.1 days. Approximately 1.2% of the shares of the company are sold short.

Virax Biolabs Group Price Performance

Shares of VRAX opened at $0.72 on Friday. Virax Biolabs Group has a one year low of $0.70 and a one year high of $8.54. The stock’s fifty day moving average is $0.87 and its 200-day moving average is $1.83.

Institutional Investors Weigh In On Virax Biolabs Group

Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of Virax Biolabs Group in the 4th quarter valued at approximately $35,000. UBS Group AG acquired a new stake in shares of Virax Biolabs Group during the 3rd quarter worth approximately $38,000. Legal & General Group Plc acquired a new stake in shares of Virax Biolabs Group during the 4th quarter worth approximately $73,000. Finally, Armistice Capital LLC acquired a new stake in Virax Biolabs Group in the 4th quarter valued at $178,000. 8.61% of the stock is currently owned by institutional investors and hedge funds.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.